Drug intelligence / Profile preview

Solubitrat

Development stage: Unknown
Lead developer: Angelini Pharma
Administration: Oral

Overview

Solubitrat is a herbal medicinal product marketed by Angelini Pharma (formerly CSC Pharmaceuticals) for the supportive treatment of inflammatory diseases of the efferent urinary tract and as a flushing agent for the prevention and treatment of kidney gravel. It is formulated as an instant tea containing dry extracts of birch leaves (*Betulae folium*) and goldenrod herb (*Solidaginis herba*). These botanical components provide diuretic, anti-inflammatory, and mild antispasmodic effects, facilitating the flushing of the urinary system to alleviate symptoms of minor urinary tract complaints such as cystitis and irritable bladder. The product is primarily available in German-speaking markets as an over-the-counter (OTC) remedy.

Brand names: Solubitrat
Other names: Solubitrat instant tea

Beyond the preview

Go deeper on Solubitrat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solubitrat.

Explore the full profile